Optimizing Treatment in Advanced RCC

Martin H. Voss, MD, provides valuable insights into determining the optimal duration of treatment with lenvatinib plus pembrolizumab in patients with advanced renal clear cell carcinoma, emphasizing the importance of close patient monitoring and the critical decision-making process involved in continuing or discontinuing treatment based on individual patient response, tolerability, and overall clinical status in real-world clinical practice settings.

EP: 1.Evolving Treatment Standards in Non-Clear Cell RCC

EP: 2.Extended Follow Up of KEYNOTE-B61

EP: 3.Ongoing Clinical Trials in the front-line setting of advanced non-clear cell RCC

EP: 4.STELLAR 304: Zanzalintinib plus nivolumab in non-clear cell RCC

EP: 5.Case Presentation: 61-year-old male Renal Cell Carcinoma

EP: 6.Use of Combination Regimens in Frontline RCC

EP: 7.Treatment Decision Making in first-line combinations for advanced RCC

EP: 8.AE Management for Combination Regimens in Advanced RCC

EP: 9.AE Management for Combination Regimens in Advanced RCC

Now Viewing

EP: 10.Optimizing Treatment in Advanced RCC

EP: 11.Dr Albiges Discusses a Non-Clear Cell RCC Patient Profile

EP: 12.Updates in the Treatment Approach for Non-clear cell RCC

EP: 13.Dr Albiges Reviews Long term follow up data from KEYNOTE-B61

EP: 14.Emerging Therapies in the Front-line Setting of Advanced non-clear cell RCC

EP: 15.Biomarker-driven combination treatment approach in non-clear cell RCC (Met-driven)

1. In your experience, what is the optimal duration of treatment with len + pembro in patients with advanced renal clear cell carcinoma?
   1. How do you monitor patients and make decisions around continuing or discontinuing treatment in clinical practice?
   2. When do you consider switching therapies versus dose reductions to maintain treatment duration?

Related Videos